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Free radicalsThe heart has complex mechanisms that facilitate the maintenance of an oxygen supply–demand balance
necessary for its contractile function in response to physiological ﬂuctuations in workload as well as in
response to chronic stresses such as hypoxia, ischemia, and overload. Redox-sensitive signaling pathways are
centrally involved in many of these homeostatic and stress-response mechanisms. Here, we review the main
redox-regulated pathways that are involved in cardiac myocyte excitation–contraction coupling, differen-
tiation, hypertrophy, and stress responses. We discuss speciﬁc sources of endogenously generated reactive
oxygen species (e.g., mitochondria and NADPH oxidases of the Nox family), the particular pathways and
processes that they affect, the role of modulators such as thioredoxin, and the speciﬁc molecular mechanisms
that are involved—where this knowledge is available. A better understanding of this complex regulatory
system may allow the development of more speciﬁc therapeutic strategies for heart diseases.poptosis repressor with caspase recruitment domain; Ca
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Conclusions .Introduction
The heart as a contractile pump has the highest O2 consumption
among all body organs and can increase consumption eightfold or
more under maximal workload conditions. Complex mechanisms
have evolved to facilitate the maintenance of a balance between
myocardial O2 supply and O2 consumption during physiological
ﬂuctuations in contractile function and workload, during growth and
differentiation, and under pathological stresses such as hypoxia,
ischemia, pressure, and volume overload. These mechanisms induce
changes in cardiomyocyte structure and/or function through coordi-
nated changes in gene and protein expression and/or the activities of
various proteins. Redox mechanisms are centrally involved in the
signaling pathways underlying many of these homeostatic mecha-
nisms, both via the direct effects of O2 levels in the cardiomyocyte and
through the effects of reactive oxygen species (ROS)1 (Fig. 1). From a
clinical perspective, much attention has focused on the concept that
oxidative stress may be a driver of cardiac disease progression (e.g.,
heart failure) but clinical interventions with antioxidants have had
little or no impact on heart disease risk and progression. Among the
reasons for the failure of such interventions, we may include the fact
that an isolated focus on oxidative stress as detrimental is far too
simplistic and neglects the wider role of ROS, redox balance (and
perhaps O2 itself) in integrated cellular signaling and heart metab-
olism. Here, we review current knowledge on the involvement of ROS
as well as O2 in modulating key signaling pathways and physiological
and pathophysiological processes in cardiac myocytes. Although we
focus on the cardiomyocyte, functional communication and cross talk
among the various cardiac cell types (i.e., cardiomyocytes, ﬁbroblasts,
endothelial cells, vessels) are also critical for normal heart function
and responses to stress [1,2].General considerations on redox signaling in cardiomyocytes
The propagation of electrons through coupled transfer partners is a
key aspect of basic O2-dependent eukaryotic cell processes such as
oxidative phosphorylation, protein folding in the endoplasmic
reticulum, the enzymatic activities of many oxygenases, and the
generation of reductive power (e.g., NADP+/NADPH; FAD/FADH2)
during metabolism. In redox signaling involving O2 or O2-derived
reactive species (ROS), the transmission and ampliﬁcation of signals
generally involves posttranslational redox protein modiﬁcations. ROS
in cardiomyocytes are generated by various sources among which the
most important are mitochondria, NADPH oxidases of the Nox family,
and nitric oxide synthases (NOSs) (Fig. 1). The quantity of ROS
generation by these various sources may increase severalfold under
different cellular contexts (e.g., disease) or upon speciﬁc stimulation
(e.g., for certain NADPH oxidases). Both one-electron oxidants (e.g.,
the free radicals O2•− and NO) and two-electron oxidants (e.g., the
nonradicals H2O2 and ONOO−) are generated, the effects of which are
inﬂuenced not only by their sites and level of production but also by
cell compartment-speciﬁc antioxidant pools and by interplay be-
tween one- and two-electron species to formmore powerful oxidants
such as •OH [3,4]. The physiological and pathological roles of •NO
generated in cardiac myocytes have been covered in recent reviews
[5–7] and are not considered in detail in this article. It should be noted,
however, that the inactivation of NO by O2•−may lead tomodulation ofsignaling pathways both as a consequence of ONOO− generation and
because of the decrease in NO bioavailability [8].
Even low concentrations of moieties such as •OH (subnanomolar)
may cause severe oxidation of macromolecules and organelles and lead
tomaladaptive cardiac dysfunction,whereas less oxidative ROS (such as
O2•−, NO, and H2O2) are commonly involved in cellular signaling that
may have an impact on both adaptive and maladaptive cardiac
responses [9] (Fig. 1). The concept that oxidative stress resulting from
an imbalance between increased ROS generation and inadequate
endogenous antioxidant pools contributes to heart failure is well
established and this may contribute to the activation of maladaptive
signaling cascades, e.g., those leading to impaired calcium (Ca) handling
—a fundamental feature of most forms of advanced heart disease. Much
less attention has been paid to the idea of cell compartment-speciﬁc or
“localized” redox signaling, which may have quite distinct and more
restricted effects. Moreover, an imbalance between ROS and antiox-
idants in the opposite direction, i.e., leading to so-called reductive stress,
has recently also been suggested to be detrimental in certain cardiac
conditions [10]. Such varying effects on cell signaling can be considered
within an overall scheme in which O2 and local compartment-speciﬁc
generation of ROS modulate signaling pathways that can potentially
drive adaptive or maladaptive stress responses. Ultimately, the balance
between such pathways determineswhether the heart adapts or fails in
different pathological settings (e.g., cardiac overload or ischemia).
Posttranslational redox modiﬁcations to myocardial proteins
(such as cysteine andmethionine thiol oxidation, proline and arginine
hydroxylation, and tyrosine nitration) may affect the conformation,
stability, and activity of diverse receptors, ion transporters (pumps/
exchangers/channels), kinases, phosphatases, caspases, translocators
(GTPases), transcription factors, and structural/contractile proteins.
Perhaps the most susceptible redox targets of “signaling” ROS such as
H2O2 are protein cysteine thiols, the oxidation of which may result in
reversible intra- or intermolecular disulﬁde formation or other thiol
modiﬁcations such as nitrosylation and glutathiolation [4,11]. The
activities of proteins such as the phosphatases PTP1B and PTEN,
caspase-3, and STAT3 are well known to be modulated by such thiol
redox switching between reduced and oxidized states [12]. In the
heart, examples of redox-modulated protein activities that may be
particularly important for cardiomyocyte function include protein
kinase A (PKA) [13], protein kinase G (PKG) [14], the ryanodine
receptor (RyR) [15], the small G protein Ras [16], class II histone
deacetylases (HDACs) [17], and the metabolic enzyme glyceralde-
hyde-3-phosphate dehydrogenase [18,19]. The balance between
oxidized and reduced forms of such signaling proteins is inﬂuenced
by both local ROS generation and reductants such as glutathione that
can reduce a wide range of oxidized proteins. A more speciﬁc
modulator of redox switching of key signaling proteins in the heart is
the protein thioredoxin 1 (Trx1), which catalyzes the reduction of
cysteine disulﬁdes and nitrosothiols in selected proteins (e.g., Ras,
apoptosis signal regulating kinase-1 (ASK1), and class II HDACs during
cardiac hypertrophy) after speciﬁc protein–protein interactions
[20,21]. Indeed, transgenic mice overexpressing Trx1 speciﬁcally in
the heart had reduced cardiac hypertrophy after overload stress
compared to wild-type mice [22]. Recent proteomic analyses
from tissues of mice with cardiac-speciﬁc overexpression of Trx1
revealed increased levels of proteins associated with the creatine–
phosphocreatine shuttle, the mitochondrial permeability transition
pore (MPTP) complex, and the contractile apparatus, suggesting that
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Fig. 1.Main ROS sources and effects in cardiacmyocytes. A diverse range of signals can initiate redox signaling, e.g., GPCR agonists, growth factors, and stresses such as hypoxia. These
may result in the induction of and/or changes in ROS generation by sources that include NO synthases (NOS), NADPH oxidases (Nox), andmitochondria. Emerging data support cross
talk among the ROS-generating systems. The main species that are generated in the ﬁrst instance are NO, O2•−, or H2O2, with recent data suggesting that Nox4 may generate
predominantly H2O2 rather than O2•−. O2-dependent metabolism also inﬂuences redox signaling signiﬁcantly, notably through changes in the generation of NADPH, which is critical
for themaintenance ofmajor antioxidant pools. ROS often act at amolecular level bymediating protein posttranslational modiﬁcations within diverse signaling pathways. In general,
low-level production of ROS may be involved in potentially adaptive processes—such as adaptation to hypoxia and modulation of excitation–contraction coupling (ECC). On the
other hand, the generation of higher levels of ROS and/or more potent oxidants such as •OH may result in signiﬁcant pathology as a result of macromolecular damage as well as
detrimental signaling.
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functions for maintaining proper cardiac energy dynamics and
facilitating contractile function [23].
Irreversible acute protein oxidation may also modulate signaling,
secondary to the proteasomal degradation of the oxidized protein. The
best example of this is probably the proline and arginine hydroxyl-
ation of the transcription factor hypoxia-inducible factor 1α (Hif1α;
see later). More commonly, severe irreversible protein oxidation
correlates with the formation of insoluble protease-resistant protein
aggregates [24]. Indeed, both aged and failing hearts show increased
levels of irreversibly oxidized protein amino acids, e.g., 3-nitrotyr-
osine [25]. The correlation between protein oxidation and aggregate
formation is, however, complex. Increased reductive power was also
found to promote the accumulation of protein aggregates in hearts
expressing a mutant αB-crystallin, a chaperone that stabilizes
cytoskeletal desmin ﬁlaments [10]. These results suggest that a ﬁne
balance between redox state and metabolism is more important than
oxidative stress per se and that an imbalance in either the oxidative or
the reductive direction could be detrimental.Role of heart metabolism
The heart in metazoan organisms exempliﬁes the major impor-
tance of oxygen metabolism for efﬁcient high-energy processes (in
particular, contractile function) on the one hand, and the use of
oxygen and ROS for modulating complex intracellular signaling
cascades on the other. The intracellular organelle content and
distribution play a key role in themetabolism and integrated signaling
network of cardiomyocytes [26,27]. Mitochondria occupy 30% of
cardiomyocyte volume and are organized in ordered rows regularly
spaced between myoﬁlaments, closely related to the sarcoplasmic
reticulum (SR), and also clustered around the nucleus. Such an
organization facilitates the functional interplay between mitochon-
drial ATP production, SR-regulated Ca homeostasis and myoﬁlament-
dependent contraction [28–30]. This architecture also favors efﬁcient
high energy output through the matching of local ATP generation and
consumption.
In contrast to organs such as brain, which depend mainly on
glucose metabolism, the adult mammalian heart normally uses lipids
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through β-oxidation of plasma fatty acids [31]. During hypoxia, under
ischemia or settings of increased cardiac workload, there is a
substantial increase in glycolytic ATP generation, which may be
cardioprotective during ischemia–reperfusion by ensuring an ade-
quate ATP supply for membrane and SR ion pumps [31,32]. Such a
metabolic shift is accompanied by changes in levels and activities of
numerous proteins involved in glucose metabolism, among which a
major increase in the expression and activity of glucose-6-phosphate
dehydrogenase (G6PDH; the rate-limiting enzyme in the pentose
phosphate pathway) contributes to the generation of NADPH. Recent
studies indicate that a metabolic shift to glycolysis has important
implications for redox status in the heart. NADPH is critical for the
maintenance of antioxidant defense through the regeneration of
reduced pools of glutathione, and G6PDH activity was shown to be of
major importance for the maintenance of redox status, Ca homeosta-
sis, and contractile function in cardiomyocytes subjected to oxidative
stress [33]. Similarly, the hearts of mice lacking G6PDH have reduced
glutathione (GSH) levels and demonstrate impaired contractile
function after ischemia–reperfusion [34]. On the other hand, it has
been suggested that increased NADPH levels may fuel NADPH
oxidase-derived ROS generation in failing hearts, and this could be
partially reversed by a G6PDH inhibitor, 6-aminonicotinamide [35]. In
this regard, the relative importance of NADPH levels for antioxidant
balance secondary to the regeneration of glutathione and thioredoxin
versus possible promotion of NADPH-dependent ROS generation (e.g.,
via NADPH oxidases) remains to be established. The intracellular
locations of the various types of NADPH-dependent processes and
their integration with cell signaling pathways may also be important.
Adding further complexity, an increased activity of the G6PDH–
NADPH pathway has also been shown to contribute to detrimental
“reductive stress” associated with increased levels of GSH in a
transgenic mouse model of cardiomyopathy caused by a mutation in
αB-crystallin [10]. In this case, the use of a G6PDH blocker could
partially rescue such detrimental effects [10]. Therefore, it may be that
an appropriate G6PDH/NADPH/GSH balance is more important than
absolute levels of glutathione.
Sources of ROS in cardiomyocytes
Mitochondrial electron transport chain-derived ROS
Mitochondria have long been recognized as one of the most
important sources of cellular ROS, which can increase severalfold
depending upon the context [36,37]. ROS are thought to be generated
mainly at complexes I and III of the electron transport chain (ETC)
through “leakage” during respiration [36,37]. It is important to
remember that mitochondrial ROS levels are inﬂuenced not only by
the ROS generation rate but also by ROS-scavenging systems. In this
regard, there is close linkage and cross talk between the redox couples
involved in substrate oxidation and the ETC (i.e., NADH/NAD+) and
those involved in antioxidant defense through NADPH-regenerating
reactions that maintain reduced pools of glutathione, glutaredoxin,
and thioredoxin, i.e., NADPH/NADP+ [38]. The precise relationship
between electron transport chain ﬂux, ROS generation, and the
mitochondrial membrane potential and the mechanisms underlying
increases in mitochondrial ROS remain controversial [38]. It has been
suggested that in settings in which the mitochondrial redox potential
is signiﬁcantly reduced (e.g., hypoxia), low electron ﬂow is accom-
panied by increased ROS generation. On the other hand, ROS levels
may also be higher in settings in which the mitochondrial redox
potential is highly oxidized, e.g., during increased workload in failing
hearts. In this case, the increase in ROS is related more to a depletion
of the antioxidant capacity as a result of decreased NADPH levels than
an increase in ROS production per se [38]. Recently, it was
demonstrated that the latter mechanism may be modulated bychanges in ionic homeostasis in failing hearts. Kohlhaas et al. [39]
found that an elevated intracellular [Na+], which leads to a reduction
in mitochondrial Ca, caused a decrease in NADPH levels during
increased workload and a consequent increase in ROS levels. The
reduction in NADPH was attributed to a decreased activity of Ca-
dependent Krebs-cycle dehydrogenases and presumably led to
reduced regeneration of antioxidant pools.
Mitochondrial ROS generation may have beneﬁcial or detrimental
effects. For example, ROS generation during cardiac ischemic
preconditioning may be beneﬁcial, as discussed later in this article.
In contrast, increased mitochondrial ROS generation in failing hearts
[40] may induce damage to mitochondrial DNA (mtDNA), e.g., after
myocardial infarction (MI) [41] or in the hypertrophied heart [42].
mtDNA is thought to be more susceptible to oxidative damage than
nuclear DNA because of the proximity of ROS generation and the lack
of protective histone. Mitochondrial ROS generation during ischemia–
reperfusion can also trigger the MPT and lead to a burst of further ROS
release—a phenomenon termed mitochondrial ROS-induced ROS
release [43]. This is not only capable of depolarizing individual
mitochondria but also can propagate among long chains of mito-
chondria and perhaps cells, thus amplifying cell injury [43,44].
Interestingly, recent studies have suggested that a transient opening
of the MPTP in quiescent unstressed cells can functionally couple to
ETC-dependent ROS production and lead to so-called “superoxide
ﬂashes” [45]. Although such ﬂashes were especially evident during
reoxygenation after anoxia in cardiomyocytes, the authors also
suggested that basally produced superoxide ﬂashes could potentially
be involved in modulating local signaling [45].
Signiﬁcant evidence for a pathological role of increased mitochon-
drial ROS in heart disease comes from studies in gene-modiﬁed mice
in which mitochondrial antioxidant levels have been perturbed. Mice
with deletion of mitochondrial thioredoxin reductase 2 are embry-
onically lethal because of impaired hematopoiesis and impaired
cardiac function [46], whereas mice with complete deletion of
mitochondrial Mn superoxide dismutase develop severe fatal dilated
cardiomyopathy [47]. In contrast, transgenic mice overexpressing
mitochondrial peroxiredoxin III [48] or glutathione peroxidase [49]
demonstrate a signiﬁcant attenuation of adverse left ventricular
remodeling post-MI. Similarly, mice with a mitochondrial-targeted
overexpression of catalase demonstrate a prolonged life span with
improved cardiac function [50] and an attenuation of cardiac aging
[51].
NADPH oxidase-derived ROS
The Nox family NADPH oxidases generate ROS (O2•− and H2O2)
through electron transfer from NADPH to molecular O2. Each of the
seven oxidase family members is based on a distinct catalytic subunit
(i.e., Nox1–5 and Duox1 and 2) and has differing requirements for
additional protein subunits [52–57]. The prototypic member of the
Nox family, Nox2 oxidase (aka gp91phox oxidase) is best known for its
role in neutrophil phagocytosis and the fact that genetic defects in the
enzyme result in chronic granulomatous disease, a condition in which
affected children suffer from recurrent severe fungal and bacterial
infections due to defective phagocyte function [52,53]. However,
Nox2 is also expressed in many other cell types and Nox family
oxidases as a whole are very widely expressed in a tissue-speciﬁc
manner. Detailed reviews on the structure, function, and roles of these
fascinating enzymes have been published recently [52–55]. Apart
from the roles of some of the Nox's (e.g., phagocyte Nox2 and
epithelial Duox's) in host defense, a large number of studies have
demonstrated that these enzymes generate ROS that are involved in
redox signaling [9,55–57]. In many cases, Nox-dependent redox
signaling involves the regulated and spatially restricted production of
low levels of ROS in the vicinity of target proteins, and such effects
have been implicated in signaling pathways that regulate processes
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migration [9,55–57].
The two Nox isoforms for which there are good data on expression
and functional effects in cardiac myocytes are Nox2 [58–61] and Nox4
[62–65] (Fig. 2). Each of these isoforms exists as a heterodimer with a
lower molecular weight p22phox subunit and is predicted to be
membrane-bound but there are several major differences between
the isoforms. Nox2 is normally quiescent and is acutely activated by
stimuli such as G-protein-coupled receptor (GPCR) agonists (e.g.,
angiotensin II, endothelin-1), growth factors, and cytokines in a
tightly regulated process in which cytosolic subunits (p47phox,
p67phox, p40phox, and Rac1) associate with the Nox2–p22phox hetero-
dimer to initiate enzyme activity [52–54]. In contrast, Nox4 does not
have a requirement for additional regulatory subunits, has constitu-
tive low-level activity, and seems to be regulated largely by changes in
abundance [52–55]. Therefore, Nox4 may be regarded as an inducible
isoform. Additionally, recent independent studies from several groups
suggest that, in contrast to Nox2, Nox4 may generate predominantly
H2O2 rather than O2•− [65–69], although it should be noted that some
papers have reported O2•− generation [70], possibly related to
experimental conditions and methodological issues. Finally, it is
clear that the intracellular locations of the two isoforms in
cardiomyocytes are distinct. There is a broad consensus that activated
Nox2 is found predominantly on the plasma membrane, whereas
Nox4 is found intracellularly [9,55–57,60,66–68]. Several groups,
including our own, have found Nox4 to be in an endoplasmic
reticulum (ER)-related perinuclear location [65] but others reported
that it may also be present in the mitochondria [64].
Nox2 may be activated by several different cardiac stresses and an
increasing body of data suggests important pathophysiological roles
for this isoform in cardiac disease [9]. Previous work from our
laboratory and others has shown that Nox2 contributes to the
development of angiotensin II-induced left ventricular hypertrophy;
to contractile dysfunction, interstitial ﬁbrosis, and apoptosis in the
pressure-overloaded or remodeling heart; and to ischemic precondi-
tioning [9,59,62,71]. Although the detailed mechanisms responsible
for these effects still remain to be deﬁned, it is clear that Nox-derived
ROS modulate several signaling pathways in cardiomyocytes, as are
discussed further later (Fig. 2). Much less has been known about the
role of Nox4 in the heart until recently, apart from it being suggested
to be involved in cardiomyogenesis [63,72]. An emerging literature
from studies in other tissues suggests that Nox4 expression increases
during stresses such as hypoxia [73], ER stress [74,75], and
mitochondrial dysfunction [76,77], and we have recently found that
myocardial Nox4 expression also increases during hypoxia, myocar-
dial ischemia, or in vivo pressure overload [62,65,71]. Furthermore,
our studies demonstrate an unanticipated protective role of this
isoform during the cardiac response to chronic pressure overload [65],
as discussed further later (Fig. 2).
Uncoupled NO synthases
Cardiomyocytes constitutively express both neuronal and endo-
thelial NOS isoforms (nNOS and eNOS, respectively), whereas
inducible NOS (iNOS) may be expressed in various pathological
situations. NO generated by nNOS and eNOS has important physio-
logical effects on myocardial contractile function [5,6]. Although we
do not discuss NO-mediated signaling in detail in this review, it
should be noted that NO-dependent nitrosylation of cysteine residues
in proteins may modulate signal transduction cascades in a manner
analogous to the effects of cysteine oxidation [78]. NOSs, however, can
also become “uncoupled” and generate O2•− in settings in which there
is a deﬁciency of the essential NOS cofactor tetrahydrobiopterin (BH4)
[79]. Because BH4 is degraded by ROS, including those derived from
Nox's [80], ROS production by uncoupled NOSs can act as an
amplifying mechanism for both the deleterious and the signalingeffects of ROS. The concomitant production of NO and O2•− is generally
associated with nitroxidative stress and protein nitration via ONOO−
or heme peroxidase-dependent nitration [3,25]. 3-Nitrotyrosine
provides a useful marker for NO-associated stress in various diseases
[81] and increased levels are found in failing hearts, notably in
proteins such as myoﬁbrillar creatine kinase, α-actinin, and sarco-
plasmic reticulum Ca2+ ATPase [25].
Other sources of ROS
Xanthine oxidoreductase exists in two forms, xanthine dehydro-
genase and xanthine oxidase (XO), which are interconvertible [82].
Only XO generates ROS, producing more O2•− or H2O2 depending on
the environmental conditions, e.g., substantially more H2O2 than O2•−
during hypoxia [83]. Upregulation of XO is reported in experimental
models of heart failure and in human end-stage failing myocardium
and its inhibition is reported to enhance mechanical efﬁciency and
improve cardiac remodeling [84,85]. Interestingly, the activity of XO is
also reported to be linked to that of nNOS such that XO-derived ROS
production is enhanced when nNOS is deﬁcient [85,86].
Apart from the ETC, there may be other sources of ROS in
mitochondria, for example, enzyme systems such as 2-oxoglutarate,
pyruvate dehydrogenase, and ﬂavoprotein acyl-CoA dehydrogenase
[36,87]. Recently, mitochondrial monoamine oxidase-A (MAO-A)
enzymes were reported to be important ROS sources through the
catabolism of prohypertrophic neurotransmitters such as norepi-
nephrine and serotonin, resulting in the generation of H2O2. In mice
with pressure overload-induced heart failure, either an MAO-A
inhibitor, clorgyline, or a dominant-negative MAO-A reduced oxida-
tive stress, inhibited contractile dysfunction, and inhibited matrix
metalloproteinase and caspase-3 activation [88].
Cardiomyocyte differentiation and proliferation
Adult cardiomyocytes are terminally differentiated cells with
absent or extremely limited proliferative capacity and therefore
differentiation and proliferation are processes that are pertinent
mainly to the developing heart. The molecular mechanisms that
underlie early cardiomyocyte differentiation have largely been
studied in vitro, often in cultured embryonic stem (ES) cell systems.
ES cells can be induced to differentiate in vitro into embryoid bodies
(EBs) comprisingmany different cell types, including cardiomyocytes,
which can be seen to “beat” in culture. An increase in the proportion of
beating cardiomyocytes in such cultures is commonly taken as a
measure of increased cardiotypic differentiation but it should be
noted that an increase in proliferative capacity of a cardiac progenitor
resulting in increased numbers of cardiomyocytes would have a
similar effect.
The overall cellular and compartment-speciﬁc redox balance is a
critical regulator of differentiation and proliferation inmany cell types
[89,90], including cardiomyocytes [91–93]. Both mechanical strain
and electrical stimulation, which increase the levels of intracellular
ROS, also increase the proportion of beating cardiomyocytes within an
EB population [72,94,95]. By contrast, agents that scavenge or reduce
ROS levels (e.g., Trolox, pyrrolidine dithiocarbamate, catalase, and N-
acetylcysteine) impair cardiomyocyte formation in EBs [63,94].
Intriguingly, however, the incubation of ES cells with H2O2 either
enhances or impairs the cardiomyogenic program, dependent upon
the concentration and timing during differentiation—suggesting both
a dose-dependency and a cellular competency in the response to ROS
[63,92,96].
It has been suggested that an important source of the ROS involved
in cardiomyogenesis is Nox4 NADPH oxidase, which is abundantly
expressed in ES cells. Li et al. [63] showed that small interfering RNA
(siRNA)-mediated downregulation of Nox4 reduced the potential of
ES cells to express cardiac-speciﬁc markers and form beating EBs, an
Fig. 2. Regulation and downstream effects of Nox2 and Nox4 in cardiac myocytes. Nox2 is normally quiescent and is activated through the binding of cytosolic regulatory
components to generate O2•−, which may react with NO or be converted to H2O2. Nox4 on the other hand is constitutively active but its expression level is increased by stresses such
as hypoxia or during development. Recent studies suggest that Nox4 generates predominantly H2O2. The downstream effects of the two Nox isoforms are divergent, with Nox2
generally driving detrimental effects, whereas Nox4 may facilitate adaptive processes such as angiogenesis. Abbreviations as in the text.
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activation of phosphatidylinositol 3-kinase seems to be required
upstream of ROS generation [91,97] and the activation of PPARα has
also been implicated [98]. Nox2 is also expressed in ES cells but the
overexpression of a dominant-negative Rac mutant that inhibits Nox2
activation did not alter the ability to form beating EBs [96], suggesting
that Nox2- and Nox4-derived ROS are functionally distinct during
early cardiomyogenesis. In Xenopus laevis embryos, the mitochondrial
respiratory chain was found to play an essential role in heart
formation through Ca-dependent activation of the transcription factor
NFAT [99]. In that study, embryos in which either of two subunits of
the respiratory chain, GRIM-19 or NDUFS3, was knocked down
showed severe defects in heart formation that could be rescued by a
constitutively active form of mouse NFATc4. Although the signaling
pathway between mitochondria and NFAT was not established in
detail, other studies have shown that mitochondrial respiration and
aerobic energy production are dispensable during very early cardio-
myocyte differentiation [100], suggesting that other mitochondrial
respiratory chain-dependent mechanisms such as ROS production
may be involved.
The molecular mechanisms involved in redox regulation of
cardiomyocyte differentiation remain poorly understood and de-
serve further study. In cardiotrophin-1-treated EBs, a ROS-depen-
dent activation of Jak-2, STAT3, and ERK1/2 and the nuclear
translocation of NF-κB were reported [97]. Also, siRNA-mediated
downregulation of Nox4 inhibited the activation of p38MAPK in ES
cells during cardiotypic differentiation [63]. Moreover, the speciﬁc
inhibition of p38MAPK signaling resulted in reduced cardiomyogen-
esis and abnormal myoﬁbrillogenesis of cardiac-committed cells
together with an impaired nuclear translocation of the cardiac-
restricted transcription factor MEF2C. In addition to changes in ROS
production, alterations in antioxidant balance may also be involved
in regulating cardiomyocyte differentiation and proliferation. For
example, in adult cardiac stem cells, the redox effector protein-1
seems to regulate ROS-dependent increases in cardiac differentia-
tion markers [93].Excitation–contraction coupling
The process of excitation–contraction coupling (ECC) is essential
for cardiomyocyte contractile activity and becomes dysregulated in
cardiac conditions such as heart failure [101]. During ECC, depolar-
ization of the sarcolemmal membrane results in the opening of
voltage-gated L-type Ca channels and subsequent Ca-induced Ca
release from the SR through the opening of RyR Ca-release channels
(Fig. 3). The binding of Ca to troponin C initiates actomyosin cross-
bridge cycling and contraction. During relaxation, Ca is actively taken
back into the SR via the SR Ca ATPase (SERCA). In addition, other
sarcolemmal ion pumps and exchangers (e.g., the Na/Ca exchanger)
and ion ﬂuxes between the cytoplasm and the mitochondria also
contribute to Ca homeostasis. The control of SR Ca release and uptake
is regulated by a specialized molecular machinery comprising the RyR
and SERCA as well as several accessory proteins, including phospho-
lamban, FKBP12.6, calsequestrin, triadin, and junctin. Appropriate
regulation of Ca cycling is essential for normal contractile function and
is a major site of potential pathologic failure, contributing not only to
contractile dysfunction but also to arrhythmia, energetic dysfunction,
and mitochondrial ROS production [101–104]. Redox signaling
involving the oxidative modiﬁcation of target proteins can affect
several components of the cardiomyocyte ECC machinery [105–107]
(Fig. 3).
Redox modulation of RyR
The cardiac RyR (RyR2) has around 90 cysteine residues per
subunit of which approximately 20 are in a reduced state and
potential targets for various redox modiﬁcations, including S-
nitrosylation, S-glutathionylation, and disulﬁde crosslinking [15].
Many in vitro studies and experiments in synthetic lipid bilayers
have convincingly demonstrated that moieties such as NO, H2O2,
nitroxyl (HNO), and hydroxyl radicals induce redox-dependent
alterations in RyR activity [106–109]. The functional consequences
of such modiﬁcation are likely to depend upon the nature,
Fig. 3. Components of the excitation–contraction coupling machinery in cardiomyocytes and the main redox-sensitive targets. The table indicates the main redox-sensitive targets
and types of protein modiﬁcation, i.e., RSSR, disulﬁde bond; RSNO, thiol nitrosylation; RSSG, thiol glutathiolation; RSO3, sulfonic acid; PTyrNO2, tyrosine nitration. In the case of
redox-activated protein kinases, the modiﬁcation is protein phosphorylation.
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chemical modiﬁcation; and the speciﬁc cysteine residues that are
affected. In skeletal muscle RyR (RyR1), it has been shown that
although some cysteines are nonspeciﬁc targets for various redox
agents, others are exclusively S-nitrosylated (Cys1040, Cys1303) or S-
glutathionylated (Cys1591, Cys3193) [110]. In general, the RyR2 open
probability and therefore SR Ca release is increased by oxidizing
conditions, whereas reducing reagents such as dithiothreitol reverse
these effects [106,110,111]. However, prolonged exposure to high
doses of oxidizing agents may cause irreversible and detrimental RyR
activation [111,112].
Although redox modiﬁcation of RyR activity is well established, its
physiological relevance and role in relation to endogenously gener-
ated oxidants remains incompletely understood. Signiﬁcant evidence
suggests that RyR2 may be modulated by NO derived from both eNOS
(under conditions of myocardial stretch) and nNOS [106,113]. Indeed,
nNOS coimmunoprecipitates with RyR2 in the heart [114] and eNOS,
which is normally found in sarcolemmal caveolae, can translocate to
the SR in failing hearts [115,116]. The effects of NO may depend upon
the level of PKA activation [113]. It has not yet been deﬁnitively
established, however, whether these effects of NO involve redox
modiﬁcation of RyR2. Additional redox-sensitive modulation may
arise from the inactivation of NO by endogenously generated O2•−. For
example, nNOS is reported to colocalize with xanthine oxidase in the
heart so that interaction between xanthine oxidase-derived ROS and
nNOS-derived NO may be relevant [86,117]. In addition, cardiac SR is
reported to have NADH oxidase activity, which inﬂuences SR Ca
release, although the nature of the oxidase was not established in that
study [118]. Hidalgo and colleagues reported the presence of a Nox2
oxidase (which utilizes NADPH rather than NADH) in cardiac and
skeletal muscle SR and found a stimulation of RyR Ca release via S-
glutathionylation [119,120], in the former case in response totachycardia. The functional effect of a transient increase in RyR open
probability in the physiological setting has been suggested to be an
augmentation of contractile force by increasing Ca transient ampli-
tude, but it is also argued that isolated transient RyR2 activation will
have no sustained effect on the Ca transient or contraction, at least in
isolated cells [121]. Recently, the positive inotropic effects of nitroxyl
donors (or HNO, the one-electron reduction product of NO) in the
form of Angeli's salt were reported to involve redox-dependent
enhancement of both RyR Ca release and SR Ca uptake [122]—
exemplifying the concept that effects additional to RyR Ca releasemay
be required to induce changes in contractile function.
Growing evidence suggests that redox modiﬁcation of RyR2 may
contribute to abnormal Ca handling in disease states. RyR2 dysfunc-
tionwith an increase in diastolic Ca leak from the SRmay reduce SR Ca
content and the Ca transient and thereby contribute to a reduced
contractile force in the failing heart as well as an increased likelihood
of arrhythmia [123,124]. Proposed mechanisms underlying such
abnormal RyR2 behavior include a hyperphosphorylation of RyR2 by
PKA [123] or calmodulin kinase II (CamKII) [125], or redox
modiﬁcation of RyR2 [126,127]. Interestingly, myocardial CamKII
activation has been found to be enhanced by ROS independent of Ca
(discussed further under myocyte apoptosis) [128], raising the
possibility that multiple redox mechanisms could contribute to
RyR2 dysfunction. Recently, it was also suggested that diastolic Ca
leak and impaired contraction in cardiomyocytes from rats with
spontaneous hypertensive heart failure was attributable not only to
increased RyR2 oxidation by xanthine oxidase-derived O2•− but also to
a reduced RyR2 nitrosylation due to less bioavailable NO [129].
Several studies in experimental models of heart failure have provided
support for a redox-dependent mechanism for RyR2 dysregulation,
including canine tachypacing models [130,131], sudden cardiac death
models [132], and a model of muscular dystrophy [133].
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It has been known for many years that SERCA may be post-
translationally modiﬁed by cysteine oxidation or tyrosine nitration,
and several of the speciﬁc residues that can be oxidatively modiﬁed
have been mapped by mass spectrometry studies in noncardiomyo-
cyte systems [134–137]. These include nitration of Tyr294 and Tyr295
[136], S-glutathiolation of Cys669 and Cys674 [135], and the oxidation
of several other cysteine residues [137]. It is suggested that low levels
of ROS may reversibly increase SERCA activity, whereas higher levels
may cause inactivation as a result of irreversible oxidative modiﬁca-
tions [134,137]. In skeletal muscle, the age-dependent decrease in
SERCA activity was suggested to be related to such oxidation of
cysteine residues [137]. In vascular smooth muscle, SERCA2b (the
dominant isoform in this tissue) has been shown to be redox-
activated via a peroxynitrite-mediated reversible S-glutathiolation at
Cys674, resulting in a reduced intracellular Ca level and vasorelaxa-
tion [135]. This mechanismwas suggested to play an important role in
NO-dependent cyclic GMP-independent vasorelaxation. Furthermore,
the irreversible oxidation of this residue rendered SERCA unrespon-
sive to NO-dependent regulation. In platelets, there is evidence for the
modiﬁcation of SERCA activity by H2O2 [138].
Although the above studies strongly support redox regulation of
SERCA as a biologically important mechanism, information on the
redox regulation of the major SERCA isoform expressed in cardiac
myocytes—i.e., SERCA2a—and the functional consequences of such
modiﬁcation is still quite limited. Tocchetti et al. [122] reported that
the positive inotropic effects of HNO involved an increase in SR Ca
uptake, and Lancel et al. [139] subsequently demonstrated that the
mechanism of this effect is an HNO-mediated reversible S-glutathio-
lation of Cys674. The same authors have recently reported that
contractile dysfunction in transgenic mice overexpressing Gαq
subunits (an establishedmodel of heart failure that involves increased
GPCR signaling) is attributable, at least in part, to a ROS-dependent
increase in SERCA2a oxidation [140]. Irreversible oxidative modiﬁca-
tions comprising sulfonylation at Cys674 and nitration at Tyr294/295
together with a reduction in maximal SERCA activity were identiﬁed,
which contributed to marked abnormalities of myocyte Ca transients
and contractile function. Crossbreeding the Gαq transgenic mice with
animals that had a cardiomyocyte-speciﬁc overexpression of catalase
reduced both Cys674 sulfonylation and Tyr294/295 nitration, restored
SERCA activity, and improvedmyocyte Ca transients and contraction—
suggesting that H2O2 was involved in these effects. The reduced
cardiomyocyte Ca transients in the setting of H2O2-induced oxidative
stress may involve a decrease in SERCA activity as well as an increase
in Na/Ca exchanger activity, which together lead to a reduced SR Ca
content [140]. Oxidation of cardiomyocyte SERCA2a associated with a
reduction in Ca uptake was also reported in a rodent model of obesity
associated with contractile dysfunction [141]. In that study, the
authors found similar effects when cardiomyocytes were treated with
angiotensin II and proposed that activation of Nox2 may be involved.
In the setting of myocardial ischemia–reperfusion, it has been
suggested that activation of the polyol pathway (comprising aldose
reductase and sorbitol dehydrogenase) contributes to irreversible
SERCA2a and RyR oxidation as a result of increased peroxynitrite
formation [142]. The treatment of isolated rat hearts subjected to
ischemia–reperfusion with polyol pathway inhibitors reduced SERCA
Cys674–SO3H (sulfonic) formation and ameliorated postischemic
contractile dysfunction. A similar mechanism of contractile dysfunc-
tion was also suggested in the setting of hyperglycemia [143].
Redox modulation of myoﬁlament proteins
Direct inhibitory effects of ROS onmyoﬁlament function have been
recognized for many years although the precise mechanisms that are
involved remain unclear [144,145]. Potential sources of such ROSinclude xanthine oxidase [146,147]. Recently, the passive stiffness of
cardiac muscle, which depends to a signiﬁcant extent on the giant
elastic protein titin, was shown to be redox-modulated through
disulﬁde bridge formation in the cardiac-speciﬁc N2-B-unique
extensible segment [148]. Elevated oxidation increased titin-based
stiffness in isolated human heart myoﬁbrils, an effect that could be
reversed by thioredoxin.
In addition to direct mechanisms, ROS may indirectly modulate
myoﬁlament function through effects on key protein kinases that
induce posttranslational phosphorylation of various myoﬁlament
proteins such as troponin I and myosin-binding protein C. Type 1
PKA is centrally involved in the positive inotropic actions of β-
adrenergic stimulation through effects on the L-type Ca channel,
SERCA2a, troponin I, andmyosin-binding protein C. Brennan et al. [13]
found that ROS-induced formation of an interprotein disulﬁde bond
between its two regulatory RI subunits leads to a subcellular
translocation and activation of the kinase. The activated PKA localizes
to myoﬁlaments through interaction with the α-myosin heavy chain
(which serves as a PKA anchor protein) and phosphorylates troponin I
and myosin-binding protein C, leading to an increase in contractile
shortening that is independent of β-adrenergic stimulation and cAMP
elevation. PKG also modulates contractile function through the
phosphorylation of troponin I [149] and it has been found that
oxidants activate PKG1α through the formation of an interprotein
disulﬁde linking its two subunits [14]. The latter mechanism was
found to contribute to NO-independent vasorelaxation [14] but
whether redox activation of PKG1α has physiological effects in
cardiac myocytes remains to be established. Redox-dependent
protein kinase C (PKC) activation was reported to increase the
phosphorylation of troponin I andmyosin-binding protein C in cardiac
myocytes and thereby to increase the Ca sensitivity of force
production [150].
Other ECC targets
Redox modiﬁcations may also affect L-type Ca channels, the
plasmalemmal Ca ATPase, the Na/Ca exchanger, and other ion
channels [106,151]. The pore-forming α1C subunit of the L-type Ca
channel contains N10 cysteine residues, and a modulation of channel
activity by thiol oxidizing agents is reported [151]. In isolated
cardiomyocytes, endothelin-1 reportedly increases the open proba-
bility of L-type Ca channels through a mechanism that involves Nox2
oxidase activation [152]. 20-Hydroxyeicosatetraenoic acid, an eicos-
anoid that is increased during ischemia–reperfusion, also activated L-
type Ca current via a Nox2/PKC-dependent mechanism [153]. The Na/
Ca exchanger comprises nine transmembrane domains and intramo-
lecular disulﬁde bonds between cysteine residues in different
domains are thought be functionally important [154]. Na/Ca exchang-
er activity is reported to be signiﬁcantly increased by ROS [155–157]
but the source of these ROS remains unclear. Angiotensin II-induced
NADPH oxidase activation is reported to reduce membrane K+
currents in streptozotocin-induced diabetes in rats [158] and
swelling-activated Cl− current in rabbit ventricular myocytes [159].
Nox2-derived ROS may also modulate the expression of ion channels,
for example, an increase in the L-type Ca channelα1C subunits [160], a
decrease in Scn5a Na+ channel mRNA abundance [161], and the
destabilization of cardiac Kv4.3 channel mRNA [162].
Myocardial hypoxia and ischemia–reperfusion
A reduction in oxygen supply (hypoxia) critically affects heart
function and is a major driver of pathophysiology in various acute and
chronic disease settings, e.g., ischemic heart disease, MI, ischemia–
reperfusion, and pressure overload hypertrophy. Prolonged hypoxia
or ischemia beyond a critical threshold results in cell death by necrosis
and/or apoptosis due to the lack of O2, disruption of Ca and pH
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oxidative DNA damage. Reperfusion (or reoxygenation) is essential
for cardiomyocyte survival but is itself associated with signiﬁcant cell
damage that is mediated at least in part via ROS-dependent
mechanisms [163]. As discussed earlier, mitochondrial ROS genera-
tion and the opening of the MPTP are thought to be causally involved
in acute reperfusion-associated damage [164].
Adaptation to hypoxia
Cardiac myocytes are generally relatively resistant to moderate
hypoxia [165]. This is largely related to hypoxia-induced activation of
a broad range of adaptive pathways, a process in which the redox-
sensitive transcription factor Hif plays a central role [166–169]. Hif1-
dependent transcription requires the dimerization of Hif1α (or
Hif2α) with Hif1β (also called aryl hydrocarbon receptor nuclear
translocator) and the recruitment of coactivators such as CBP/p300.
The primary regulator of Hif1 transcriptional activity is the level of
Hif1 or 2α, which is very low under normoxic conditions but becomes
elevated during hypoxia or in response to certain other stimuli—
notably those that generate ROS. In the presence of oxygen, prolyl
hydroxylase dioxygenase family enzymes (PHD1–3) hydroxylate Hif-
α at conserved proline residues (i.e., Pro402 and Pro564) in a process
that requires nonheme Fe(II), ascorbate, and 2-oxoglutarate
[168,170]. Hydroxylated Hif-α binds to the von Hippel-Lindau
(vHL)–E3 ligase and is targeted for rapid proteasomal degradation.
PHD activity is substantially inhibited during hypoxia, leading to
increased Hif-α levels and an increase in the transcription of a
multitude of Hif-regulated genes—including genes involved in
regulating O2 delivery and consumption, glycolysis, glucose metab-
olism, mitochondrial function, cell survival, antioxidant defense,
angiogenesis, and many others. During sustained chronic hypoxia,
PHD levels themselves are also upregulated and act as a brake on
sustained Hif activation, which is thought to be detrimental [171].
In addition to the direct effects of a reduction in O2 levels, an
increase in ROS also results in Hif activation through other
mechanisms that increase Hif1α levels. The transcription of both
Hif1α and Hif2α is redox-sensitive [166,167], whereas Hif1α
translation may also be subject to redox regulation via changes in
the activity of mTOR [172]. In addition, PHD activity is inhibited by
ROS, potentially through oxidation of the nonheme iron and/or
reduction in ascorbate levels [173]. It is worth noting that NO also has
similar effects on Hif1α [174]. During hypoxia, both mitochondrial
ROS [175,176] and those derived from NADPH oxidases—in particular,
Nox4 [65,177]—may contribute to Hif activation. Nox4 levels increase
in response to hypoxia in ﬁbroblasts [73] and cardiomyocytes [65],
and we have recently reported that a major mechanism underlying
cardiomyocyte Hif activation during hypoxia is a Nox4-dependent
increase in Hif1α levels secondary to reduced Hif1α hydroxylation at
both Pro402 and Pro564 residues [65].
The activation of Hif-regulated genes is likely to contribute to
protection during and/or after ischemia through several mechanisms
such as an increase in glycolytic capacity, enhanced antioxidant
defense, activation of cell survival pathways, and an increase in
angiogenesis. Indeed, increased levels of Hif1α and Hif-regulated
genes such as heme oxygenase-1 (HO-1), iNOS, and VEGF are found in
the peri-infarct zone after MI [178,179]. Mice with a cardiomyocyte-
speciﬁc deletion of Hif1α demonstrate a reduction in vascularization,
contractility, and high-energy phosphate content that is attributable
to the altered expression of genes involved in angiogenesis, calcium
handling, and glucosemetabolism, indicating a major role for Hif1α in
coordinating energy availability and utilization in the heart [180].
Transgenic overexpression of HIF1α in the myocardium of mice
reduces infarct size and improves cardiac function 4 weeks after MI in
association with evidence of increased capillary density in the peri-
infarct region [181]. Similarly, the siRNA-mediated silencing of PHDexpression in murine hearts in vivo was found to increase HIF1α
protein stabilization and to decrease infarct size and cardiac
dysfunction after ischemia–reperfusion [182]. These effects seemed
to involve Hif1-induced increases in iNOS (which has been shown
to be cardioprotective in several studies) because they were lost in
iNOS−/−mice [183]. Other studies have implicated increases in HO-1
as a downstream mediator of Hif1-dependent reduction in cardiac
ischemia–reperfusion injury [184]. Hif1 activation may also have
favorable effects in nonischemic cardiac pathology, such as pressure-
overload hypertrophy, which is discussed in a later section. Although
the data described above indicate that short-term Hif1 activation is
protective after MI, it should be noted that several studies suggest that
chronic sustained activation of the Hif1 pathway in ischemic
myocardium may be maladaptive. For example, mice with a cardiac-
speciﬁc deletion of vHL [185], a genetic deletion of PHD2/3 [186,187],
or overexpression of an O2-insensitive form of Hif1α [188] all develop
severe cardiomyopathy.
Ischemic preconditioning
Transient episodes of myocardial ischemia are protective against
cell injury and death caused by subsequent prolonged ischemia, a
phenomenon known as ischemic preconditioning [189,190]. In
addition to ischemia per se, such cardioprotection can be evoked by
a wide variety of stimuli, notably many GPCR agonists. The pathways
underlying this potent phenomenon still remain incompletely
understood but inhibition of the MPT is considered an important
terminal mechanism. Many studies have suggested that redox
signaling during the initial preconditioning period may be involved
in the eventual cardioprotective effect, at least for some stimuli that
evoke preconditioning [191–194]. These signaling ROS can be derived
from mitochondria (related to slight mitochondrial swelling and an
increase in respiration) [193] or from Nox2 NADPH oxidase [195,196]
and are thought to act through the redox activation of PKC, although it
is possible that other kinases involved in preconditioning could also
be redox-activated. Several studies have suggested that the signaling
pathways activated by diverse preconditioning stimuli converge on
glycogen synthase kinase-3β (GSK-3β), the phosphorylation and
inactivation of which inhibits the MPTP, although the precise
molecular target(s) of GSK-3β remains to be established [193,197].
However, some studies have argued against a central role for GSK-3β
inhibition in preconditioning (e.g., [198–200]).
Preconditioning triggers not only induce immediate protection
against ischemia–reperfusion injury but also provide delayed protec-
tion 24 hours or more after the initial trigger—termed delayed or late
preconditioning. Several Hif-dependent genes are implicated in late
ischemic preconditioning, for example, iNOS [201], cyclooxygenase-2
[202], and HO-1 [203], suggesting that redox signaling may be
involved. The protective effect may, in part, involve an upregulation of
antioxidants such as HO-1 and other proteins [203].
Cardiac hypertrophy
Chronic increases in cardiac workload result in heart hypertrophy,
a situation in which there is a signiﬁcant increase in cardiomyocyte
size that contributes to increased chambermass andwall thickness. In
“physiological” hypertrophy, e.g., with chronic endurance exercise or
pregnancy, the increase in size is an adaptation to the increased
workload and is associated with the maintenance of normal
contractile function and the absence of long-term ill effects. In
contrast, persistent “pathological” hypertrophy, e.g., with chronic
hypertension or after MI, is associated with a progressive energetic
deﬁcit, contractile dysfunction, and eventual heart failure. As well as
changes at the cardiomyocyte level, pathological hypertrophy is
characterized by signiﬁcant rarefaction of myocardial capillaries and
major changes in the extracellular matrix that lead to ﬁbrosis and
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adaptive versusmaladaptive programs of gene and protein expression
that contribute to these abnormalities and the balance between these
may determine whether the heart fails [204–206]. Abnormalities in
myocyte ECC and tissue hypoxia (both discussed earlier) and the
occurrence of myocyte apoptosis (discussed later) are important
contributors to the development of heart failure. In this section, we
focus on ROS-modulated pathways that promote cardiomyocyte
hypertrophy as well as those that are protective in this setting (Fig. 2).
Hypertrophic pathways modulated by endogenous ROS
Numerous experimental studies have reported that exogenous
ROS can modulate many signaling pathways known to be involved in
cardiomyocyte hypertrophy, such as the activation of ERK1/2, JNK,
p38MAPK, Akt, PKCs, and NF-κB [207]. Here we focus on studies that
have addressed the involvement of endogenous ROS in hypertrophic
signaling pathways, identiﬁed the sources of such ROS, and/or
provided information on molecular mechanisms involved in such
redox signaling.
Cardiomyocyte hypertrophy induced by GPCR agonists such as
angiotensin II, α-adrenoceptor agonists, and endothelin-1 has been
shown to involve endogenous ROS generation and the activation of
ERK1/2 and NF-κB [208–210]. In the case of α-adrenoceptor
stimulation, it was demonstrated that the Trx1-sensitive oxidation
of speciﬁc cysteine thiols on the small G protein Ras is a key molecular
mechanism that induces activation of the Ras–Raf–MEK1/2–ERK1/2
signaling pathway leading to cardiomyocyte hypertrophy [211].
Another molecular mechanism that has been elegantly dissected is
the Trx1-sensitive oxidation of class II HDACs [17], which are master
negative regulators of cardiac hypertrophy that inhibit the transcrip-
tion of MEF2-dependent genes [204,206]. It was found that Trx1 forms
amultiprotein complexwith HDAC4 and a heat shock protein, DnaJb5,
in cardiomyocytes. During α-adrenoceptor-induced cardiomyocyte
hypertrophy, speciﬁc cysteine residues in HDAC4 (Cys667, Cys669)
and DnaJb5 (Cys274, Cys276) were oxidized to form intramolecular
disulﬁde bonds, leading to the phosphorylation-independent nuclear
export of HDAC4 and the induction of hypertrophy [17].
Redox-dependent activation of the MAPKKK ASK1 has been
implicated upstream of NF-κB activation in GPCR-induced hypertro-
phy [210]. Tumor necrosis factor-α (TNFα)-induced cardiomyocyte
hypertrophy was also reported to involve ROS-dependent activation
of NF-κB [212]. These investigators subsequently showed that Ca-
dependent activation of Pyk leads to Rac1 activation [213], which is
itself upstream of ASK1 and NF-κB activation [214], raising the
possibility that cardiomyocyte Nox2 (which requires Rac1 for its
activation) may the ROS source. Indeed, Nox2 has been conﬁrmed to
be involved in cultured cardiomyocyte hypertrophy induced by
angiotensin II [215,216] and endothelin-1 [217], and Hingtgen et al.
[216] provided evidence that Akt activation may also be involved.
Further strong evidence for an involvement of Nox2 in angiotensin II-
induced cardiac hypertrophy comes from in vivo studies in gene-
modiﬁed mice. We found that hypertrophy induced by chronic
angiotensin II infusion was signiﬁcantly inhibited in Nox2-null mice
independent of changes in blood pressure, in conjunction with a
failure to increasemyocardial NADPH oxidase activity [59]. Satoh et al.
[218] reported that angiotensin II-induced in vivo cardiac hypertro-
phy was similarly inhibited in mice with a cardiomyocyte-speciﬁc
deletion of Rac1 in conjunction with a reduction in Nox2 activation.
Angiotensin II-induced in vivo cardiac hypertrophy was also inhibited
in ASK1-null mice [219].
Redox signaling is also implicated in pressure-overload-induced
cardiac hypertrophy [220]. Mechanical strain may be at least one
prohypertrophic stimulus during pressure overload and it has been
shown that mechanical stress-induced cardiomyocyte hypertrophy
may involve Rac1–ROS-dependent pathways that activate ERK1/2[221] and p38MAPK [222], consistent with the involvement of Nox2.
ROS-dependent S-glutathiolation of Ras at Cys118 and consequent
activation of the Raf–MEK–ERK pathway were involved in mechanical
strain-induced hypertrophy [223], similar to ﬁndings in GPCR-
induced hypertrophy [211]. The expression and activation of Nox2
do in fact increase during chronic pressure overload [58,224,225], and
increases in Nox2 expression and activity have also been demon-
strated in myocardial samples from failing human hearts
[60,226,227]. Mice with a cardiomyocyte-speciﬁc deletion of Rac1
were protected against pressure-overload hypertrophy [218] and
Nox2-null mice developed less contractile dysfunction than wild-type
littermates when subjected to chronic pressure overload [228],
supporting a prohypertrophic role of Nox2. However, the extent of
hypertrophy in Nox2-null mice was similar to that in wild-type
littermates [62,229,230], suggesting that although Nox2 can exert
prohypertrophic effects during chronic pressure overload other
pathways may compensate in its absence.
Redox-sensitive protective pathways activated during cardiac
hypertrophy
We have recently identiﬁed a potent Nox4-dependent protective
pathway that is activated during chronic pressure overload [65].
Earlier studies had shown that although the level of Nox4 is low in the
healthy adult heart, its expression increases signiﬁcantly during
pressure overload or after myocardial ischemia [62,71]. It was
therefore speculated that Nox4 might compensate for Nox2 in the
setting of pressure overload hypertrophy. As discussed under Sources
of ROS in cardiomyocytes, however, the two Nox isoforms exhibit
signiﬁcant differences in regulation, activation, subcellular location,
and nature of ROS generation. Nox4, unlike Nox2, does not require
agonist stimulation and is regulated mainly by its expression level
[66,67]. It is found in an intracellular perinuclear location [65] in
contrast to activated Nox2, which is located at the cardiomyocyte
sarcolemmal membrane [60]. Furthermore, Nox4 seems to generate
predominantly H2O2 rather than O2•−, in contrast to Nox2 [65–69]. To
investigate the role of Nox4 during pressure overload, we generated
mouse models with a deletion of Nox4 or a cardiomyocyte-targeted
increase in Nox4 expression. Neither model developed signiﬁcant
changes in cardiac hypertrophy or function in the absence of stress,
and therewere no changes inmyocardial Nox2 levels [65]. In response
to chronic pressure overload, however, Nox4-null mice developed
signiﬁcantly greater cardiac hypertrophy and contractile dysfunction
than control animals, whereas Nox4-transgenic mice exhibited
protection against pressure-overload-induced hypertrophy and fail-
ure. Investigation of the mechanisms underlying the protective effect
of Nox4 revealed that it facilitated the preservation of myocardial
capillary density during pressure overload by augmenting stress-
induced cardiomyocyte Hif1 activation and the release of VEGF,
resulting in increased paracrine angiogenic activity [65]. The main
mechanism by which Nox4 regulated cardiomyocyte Hif1 activation
was through inhibition of Hif prolyl hydroxylase activity and a
subsequent increase in Hif1α protein levels. These data extend the
ﬁndings from recent studies showing that the extent of myocardial
capillarization is a key determinant of functional cardiac compensa-
tion during chronic pressure overload [231,232], with Hif1 being a
major driver of this process [233]. An insufﬁcient increase in capillary
number relative to the increase in cardiomyocyte size during
hypertrophy may promote pathological remodeling of the heart
with increased hypertrophy, ﬁbrosis, cardiac dilatation, and contrac-
tile failure. Whether other Nox4-dependent antihypertrophic path-
ways are also involved in its beneﬁcial effects requires further
investigation. The above data on Nox4 taken together with previous
studies on Nox2 indicate that the two isoforms contrast markedly in
their effects during pressure-overload-induced cardiac hypertrophy,
with Nox2 being detrimental and Nox4 beneﬁcial (Fig. 2). It should be
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deletion and overexpression suggested that Nox4 contributed to
detrimental O2•− production, which enhanced heart failure in response
to pressure overload, although no effects on cardiac hypertrophywere
found in that study and Hif1 activation was not studied [70]. The
reasons for this discrepancy remain to be elucidated but the ﬁnding of
substantial Nox4-dependent O2•− production in this study is at odds
with recent data from several independent laboratories that Nox4
generates predominantly H2O2 rather than O2•− [65–69,234,235]. It
should also be noted that persistent Hif1 activation in the setting of
pathological cardiac hypertrophy could be detrimental by promoting
maladaptive metabolic changes in glycolytic and lipid anabolic
pathways [236].
Myocyte apoptosis
Cardiomyocyte apoptosis is recognized to be important in both
ischemia–reperfusion injury and the transition from compensated
cardiac hypertrophy to heart failure, at least in part through redox-
dependent mechanisms [237,238]. The signaling pathways that
regulate apoptosis in cardiomyocytes have been reviewed in detail
[237,238] In brief, apoptosis may be activated by extrinsic or intrinsic
pathways. The extrinsic pathway is stimulated by factors such as
TNFα that cause the formation of a death-inducing signaling complex,
which leads to the activation of a cascade of caspases and eventual
caspase-3-mediated proteolysis of intracellular proteins and oligonu-
cleosomal DNA cleavage. The intrinsic apoptotic pathway uses
mitochondria to evoke cell death through the opening of the MPTP
or the permeabilization of the outer membrane, resulting in the
release of cytochrome c and other proteins (e.g., apoptosis-inducing
factor, AIF) into the cytoplasm. Cytochrome c facilitates the formation
of an apoptosome complex with apoptotic protease activating factor-
1, dATP, and caspase-9 and leads to caspase-3 activation. Bcl-2 family
proteins are key regulators of mitochondrial membrane integrity in
apoptosis and comprise proapoptotic (e.g., Bax, Bak) and antiapopto-
tic proteins (e.g., Bcl-2, Bcl-xL) that are transcriptionally and
posttranslationally regulated. BH3-only proteins are additional
death effectors that can activate proapoptotic or inactivate antiapop-
totic Bcl-2 family members.
The importance of oxidative stress in cardiomyocyte apoptosis is
illustrated by the ﬁnding that the overexpression of various
antioxidant proteins, including catalase [221], glutathione peroxidase
1 [49], metallothionein [239], mitochondrial glutaredoxin-2 [240],
and peroxiredoxin II [241], reduces apoptosis and improves contrac-
tile dysfunction after ischemia–reperfusion injury in mice in vivo.
Oxidative stress activates the intrinsic apoptotic pathway in cardio-
myocytes (e.g., during ischemia–reperfusion) through multiple
mechanisms, such as the induction of MPTP opening, DNA damage-
induced activation of the p53 transcription factor, translocation of Bax
and Bad to themitochondria, and caspase activation [237,238,242]. An
alternativemode of oxidative stress-induced activation of the intrinsic
apoptotic pathway may involve induction of the ER stress response,
leading to caspase-12 activation and/or Ca-dependent opening of the
MPTP [238]. During oxidative stress, p53 induces the E3 ubiquitin
ligase, MDM2, which promotes the ubiquitination and proteasomal
degradation of a key antiapoptotic regulator, ARC (apoptosis repressor
with caspase recruitment domain), which is known to interact with
Bax and inhibit apoptosis involving the mitochondrial pathway [243].
This seems to be an important pathogenic mechanism based on the
ﬁndings that overexpression of ARC inhibits oxidant-induced apo-
ptosis in isolatedmyocytes [244] and that ARC knockout mice develop
larger infarcts after ischemia–reperfusion and more rapidly develop
pressure-overload-induced heart failure [245]. However, it should be
noted that MDM2may have complex effects because it also promotes
the degradation of p53 itself, whichmay be cardioprotective [246]. AIF
also provides protection against oxidative stress-induced apoptosis incardiomyocytes, and AIF-deﬁcient mice show increased apoptosis and
faster progression to heart failure when subjected to chronic pressure
overload [247].
GPCR signaling induced by catecholamines, angiotensin II, prosta-
glandin F2α, or endothelin-1, which induces cardiomyocyte hyper-
trophy, may also induce apoptosis at higher intensities of GPCR
activation. One mechanism that has been quite well characterized is a
Gαq-mediated PKC-dependent transcriptional upregulation of the Bcl-
2 family member Nix, which activates the mitochondrial death
pathway [248]. PKC activation is potentially redox-sensitive but
whether this is involved in the upregulation of Nix remains to be
established. Cardiomyocyte apoptosis induced by 5-HT was shown to
involveMAO-A-dependent ROS generation, which led to upregulation
of Bax and downregulation of Bcl-2 and subsequent mitochondrial
release of cytochrome c [249]. Other pathways linking GPCR
activation and the induction of apoptosis may involve the activation
of kinases such as ASK1, JNK, and p38MAPK [250]. In adult rat
cardiomyocytes, β-adrenoceptor-induced apoptosis was shown to
involve ROS-dependent activation of JNK, which in turn activated the
mitochondrial death pathway and cytochrome c release [251]. ASK1
may be redox-activated upstream of p38MAPK and JNK to induce
cardiomyocyte apoptosis, and ASK1 activity and ASK1-dependent
apoptosis are inhibited by Trx1 and Trx2 [252].
A novel redox mechanism involved in angiotensin II-induced
cardiomyocyte apoptosis has recently been identiﬁed as the Ca-
independent activation of CamKII as a result of the oxidation of
methionine residues 281 and 282 in the regulatory domain of the
kinase [128]. In vivo oxidative activation of CamKII in the hearts of
mice infused with angiotensin II was accompanied by increased
apoptosis, which was inhibited in mice overexpressing an inhibitory
peptide against CamKII (AC3-I). The authors also provided evidence
that the ROS responsible for CamKII activation and apoptotic death via
the mitochondrial pathway were derived from Nox2 oxidase
activation (Fig. 2), because the effects were abolished in mice lacking
p47phox (which is essential for Nox2 activity) [128]. The methionine
oxidation of CamKII is reversible by methionine sulfoxide reductase A
(MsrA) and mice deﬁcient in MsrA were found to exhibit exaggerated
CamKII oxidation, cardiomyocyte apoptosis, cardiac dysfunction, and
mortality after myocardial infarction [128]. Interestingly, however,
isoproterenol induced activation of CamKII, and induction of apopto-
sis did not involve ROS. Palomeque et al. [253] also reported a similar
angiotensin II-induced ROS-dependent cardiomyocyte apoptotic
pathway involving CamKII activation and found that p38MAPK
activation was downstream of CamKII in the proapoptotic pathway.
It should be noted that recent studies in various noncardiomyocyte
settings have reported that Nox4-derived ROS may inhibit apoptosis,
e.g., in pulmonary ﬁbroblasts [73], human glioma cells [254],
pancreatic carcinoma cells [255–257], and hepatocytes [258]. The
mechanisms involved in Nox4-dependent antiapoptotic effects may
include the activation of kinases such as Akt [257] and Jak-2 [259].
Whether such ROS-dependent antiapoptotic effects are relevant in
cardiomyocytes remains to be established.
Conclusions
In this article, we have reviewed the main redox-regulated
physiological and pathological pathways that are involved in cardiac
myocyte ECC, growth, differentiation, hypertrophy, survival, and
responses to stresses such as hypoxia, ischemia, and chronically
increased workload. The sources of the endogenously generated ROS
that are involved in modulating these various pathways are gradually
being identiﬁed and it is increasingly evident that in many cases,
regulatory pathways are source-speciﬁc. A number of molecular
mechanisms through which ROS modulate speciﬁc pathways in
cardiomyocytes have been deﬁned (e.g., the redox activation of RyR,
PKA, and Ras, or the posttranslational modiﬁcation of HDAC4) but
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posttranslational protein modiﬁcations mediated by ROS, redox
protein recycling systems such as Trx1 and glutaredoxin and the
metabolic processes that inﬂuence redox status (e.g., through the
regeneration of antioxidant pools) are of major importance. The latter
are especially sensitive to the cardiomyocyte O2 supply, and the
interrelationship between the direct effects of O2 levels and ROS-
dependent regulation is also a key aspect of redox signaling in the
cardiomyocyte. The data reviewed in this article clearly show that
redox signaling is integral to the maintenance of cardiomyocyte
homeostasis and is centrally involved in the integrated cellular
signaling machinery that underlies cardiac responses to stress. Future
work in the ﬁeld needs to better address several key aspects that
include (a) cardiomyocyte compartment-speciﬁc redox regulation
and signaling in various settings, (b) mechanisms that regulate and
integrate intercompartmental signaling, (c) the integration of speciﬁc
ROS generation with antioxidant balance and metabolic processes
(whichmay be especially important inmyocytes), (d) the detrimental
and/or protective roles of speciﬁc ROS generators, and (e) the
identiﬁcation of key molecular mechanisms that could be therapeu-
tically targeted. A better understanding of this complex regulatory
system may allow the development of more speciﬁc therapeutic
strategies for heart diseases.Acknowledgments
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